VERU INC. Accretion Expense
VERU INC. (VERU) reported Accretion Expense of $4.37 million for the 12-month period ending 2022-09-30, per its 10-K filed 2022-12-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2022-12-05
- VERU INC. accretion expense for the quarter ending 2022-09-30 was $812.32K, a 25.96% decline year-over-year.
- VERU INC. accretion expense for the quarter ending 2022-06-30 was $1.19M, a 24.45% increase year-over-year.
- VERU INC. accretion expense for the quarter ending 2022-03-31 was $1.21M, a 63.84% increase year-over-year.
- VERU INC. accretion expense for the quarter ending 2021-12-31 was $1.16M, a 92.20% increase year-over-year.
- VERU INC. accretion expense for fiscal 2022 was $4.37M, a 28.78% increase from fiscal 2021.
- VERU INC. accretion expense for fiscal 2021 was $3.39M, a 139.55% increase from fiscal 2020.
- VERU INC. accretion expense for fiscal 2020 was $1.42M, a 147.46% increase from fiscal 2019.
- VERU INC. accretion expense for fiscal 2019 was $572.29K, a 184.40% increase from fiscal 2018.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2022-09-30 | $812.32K derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-05 | $2.00M derived: sum of 2 quarters · filed 2022-12-05 | $3.21M derived: sum of 3 quarters · filed 2022-12-05 | $4.37M 10-K · filed 2022-12-05 |
| 2022-06-30 | $1.19M 10-Q · filed 2022-08-11 | $2.40M derived: sum of 2 quarters · filed 2022-08-11 | $3.56M 10-Q · filed 2022-08-11 | $4.65M derived: sum of 4 quarters · filed 2022-12-05 |
| 2022-03-31 | $1.21M 10-Q · filed 2022-05-12 | $2.37M 10-Q · filed 2022-05-12 | $3.47M derived: sum of 3 quarters · filed 2022-12-05 | $4.42M derived: sum of 4 quarters · filed 2022-12-05 |
| 2021-12-31 | $1.16M 10-Q · filed 2022-02-09 | $2.26M derived: sum of 2 quarters · filed 2022-12-05 | $3.21M derived: sum of 3 quarters · filed 2022-12-05 | $3.95M derived: sum of 4 quarters · filed 2022-12-05 |
| 2021-09-30 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-05 | $2.05M derived: sum of 2 quarters · filed 2022-12-05 | $2.79M derived: sum of 3 quarters · filed 2022-12-05 | $3.39M 10-K · filed 2022-12-05 |
| 2021-06-30 | $952.28K 10-Q · filed 2022-08-11 | $1.69M derived: sum of 2 quarters · filed 2022-08-11 | $2.30M 10-Q · filed 2022-08-11 | $2.78M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $740.18K 10-Q · filed 2022-05-12 | $1.34M 10-Q · filed 2022-05-12 | $1.83M derived: sum of 3 quarters · filed 2022-05-12 | $2.20M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $602.86K 10-Q · filed 2022-02-09 | $1.09M derived: sum of 2 quarters · filed 2022-02-09 | $1.46M derived: sum of 3 quarters · filed 2022-02-09 | $1.76M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-09-30 | $487.33K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-02 | $856.47K derived: sum of 2 quarters · filed 2021-12-02 | $1.16M derived: sum of 3 quarters · filed 2021-12-02 | $1.42M 10-K · filed 2021-12-02 |
| 2020-06-30 | $369.14K 10-Q · filed 2021-08-12 | $669.66K derived: sum of 2 quarters · filed 2021-08-12 | $928.84K 10-Q · filed 2021-08-12 | $1.14M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $300.52K 10-Q · filed 2021-05-12 | $559.70K 10-Q · filed 2021-05-12 | $768.47K derived: sum of 3 quarters · filed 2021-05-12 | $915.69K derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $259.18K 10-Q · filed 2021-02-10 | $467.95K derived: sum of 2 quarters · filed 2021-02-10 | $615.17K derived: sum of 3 quarters · filed 2021-02-10 | $739.12K derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-09-30 | $208.77K derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-10 | $356.00K derived: sum of 2 quarters · filed 2020-12-10 | $479.94K derived: sum of 3 quarters · filed 2020-12-10 | $572.29K 10-K · filed 2020-12-10 |
| 2019-06-30 | $147.22K 10-Q · filed 2020-08-13 | $271.17K derived: sum of 2 quarters · filed 2020-08-13 | $363.52K 10-Q · filed 2020-08-13 | $442.61K derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $123.95K 10-Q · filed 2020-05-13 | $216.30K 10-Q · filed 2020-05-13 | $295.39K derived: sum of 3 quarters · filed 2020-05-13 | $390.24K derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $92.35K 10-Q · filed 2020-02-12 | $171.44K derived: sum of 2 quarters · filed 2020-02-12 | $266.30K derived: sum of 3 quarters · filed 2020-02-12 | $293.58K derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-09-30 | $79.09K derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-12 | $173.95K derived: sum of 2 quarters · filed 2019-12-12 | $201.22K derived: sum of 3 quarters · filed 2019-12-12 | $201.22K 10-K · filed 2019-12-12 |
| 2018-06-30 | $94.86K 10-Q · filed 2019-08-08 | $122.14K derived: sum of 2 quarters · filed 2019-08-08 | $122.14K 10-Q · filed 2019-08-08 | |
| 2018-03-31 | $27.28K 10-Q · filed 2019-05-15 | $27.28K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |